Bariatric Surgery Combined With GLP-1 Receptor Agonists Study (opens ClinicalTrials.gov)
- Sponsor
- China-Japan Friendship Hospital
- Enrolment
- 200
- Started
- 2024-01-01
- Last update
- 2026-04-23
Conditions: Obesity
Interventions: BS-GLP group, BS group
Research discovery
— registered studies
Verify this search on the official site ↗ · fetched Nov 5, 2026, 12:10 PM UTC
Status on this page
A registered trial is a plan, not a result. “Results posted” means the sponsor uploaded summary results to the registry; it says nothing about whether the treatment worked.
Conditions: Obesity
Interventions: BS-GLP group, BS group
Conditions: Obesity
Interventions: Semaglutide, Placebo
Conditions: Obesity
Interventions: Semaglutide
Conditions: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Interventions: SGLT2 inhibitor, GLP-1 RA
Conditions: Obesity
Interventions: Resistance exercise, Protein Intake
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary…
Interventions: Semaglutide Pen Injector
Conditions: Diabetes Mellitus, Type 2
Conditions: Sleep Apnea Syndrome (OSAS)
Interventions: Semaglutide Subcutaneous Injection
Conditions: Nausea and Vomiting, Obesity
Interventions: Tradipitant, Placebo
Conditions: Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Conditions: Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification…
Interventions: GLP-1 receptor agonist, Lifestyle intervention
Conditions: Obesity, Appetite Regulation, PreDiabetes
Interventions: Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj
Conditions: Obesity
Interventions: Surveys, Indirect Calorimetry, Body composition, Anthropometrics
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions: Semaglutide Pen Injector, Placebo
Conditions: Obesity, Overweight
Interventions: WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
Conditions: Obesity, Weight Management
Interventions: XW003 injection, semaglutide injection
Conditions: Type2Diabetes, ASCVD
Interventions: SGLT2 inhibitor, GLP-1 receptor agonist
Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
Conditions: Weight Management
Interventions: HD1916, semaglutide
Conditions: Overweight or Obesity
Interventions: SYH9017, Placebo, Wegovy ®